Weight loss drug ‘Ozempic’ approved for use in India: What we need to know about its health benefits and risks

India has officially approved the use of Ozempic (semaglutide), a once-a-week injection designed for adults with type 2 diabetes. Approved by the Central Drugs Standard Control Organisation (CDSCO), this drug has made headlines worldwide not just for diabetes management but also for its weight loss effects. As India faces rising rates of diabetes, Ozempic’s arrival is more than just a medical update, it could influence lifestyle choices for millions.

Here’s all we need to know about what this new development means, its potential benefits, risks, and lifestyle implications.

What exactly is Ozempic?

Ozempic is the brand name for semaglutide, part of a class of drugs called GLP-1 receptor analogues. According to ANI, “Semaglutide Injection (Ozempic@) is indicated for the treatment of Adults with Insufficiently Controlled Type 2 Diabetes Mellitus as an adjunct to Diet and Exercise.”

Simply put, it mimics a natural hormone in the body, helping to control blood sugar levels. Administered once a week, it’s designed to complement healthy eating and physical activity. Beyond diabetes, it has shown promise in supporting weight management, making it a unique option for those tackling both conditions.
How Ozempic works for blood sugar

Ozempic works in multiple ways:

  • Boosts insulin production when blood sugar rises.
  • Reduces glucagon secretion, which prevents unnecessary sugar release from the liver.
  • Slows gastric emptying, helping people feel full for longer.
  • India is often called the world’s diabetes capital, with millions struggling to manage type 2 diabetes.

Access to innovative drugs like Ozempic could significantly improve health outcomes. According to Vikrant Shrotriya, Managing Director of Novo Nordisk India, “We strive to introduce the best-in-class innovations for the people who need it the most.”

Benefits that stand out

Ozempic offers several benefits that go beyond basic blood sugar control:

Effective glycemic control: Helps maintain stable blood sugar levels, reducing diabetes complications.

Cardiovascular protection: Studies suggest that it reduces the risk of major heart problems, a major concern for Indian patients with diabetes.

Potential liver health boost: Early studies suggest benefits for fatty liver, a common issue in urban populations.
It’s not just a drug; it can subtly support lifestyle improvements by controlling cravings and helping maintain healthier eating habits.

Possible risks and side effects

No drug is without caution. Ozempic users have reported:

  • Nausea, vomiting, or stomach upset.
  • Risk of pancreatitis and gallbladder issues.
  • Kidney complications in some users.
  • Mood changes or anxiety in certain cases.

Related Posts

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

New Delhi: The entry of semaglutide generics in India is ‘stimulating’ market growth and providing a favourable push to Eli Lilly’s blockbuster brand Mounjaro (tirzepatide), said Patrik Jonsson, Executive Vice…

Pak-made illegal cosmetics recovered from Itwari shop

Nagpur: Maharashtra Food and Drug Administration (FDA), Nagpur Division, raided a cosmetics firm in Itwari market and seized Pakistan-origin beauty products suspected to have harmful mercury and steroids last week. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Pak-made illegal cosmetics recovered from Itwari shop

Pak-made illegal cosmetics recovered from Itwari shop

Licences of 20 medical stores suspended after inspections

Licences of 20 medical stores suspended after inspections

Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

HP accounts for 47 inferior drugs in March alert

HP accounts for 47 inferior drugs in March alert